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Abstract
Background: Ocular surface squamous neoplasia (OSSN) is a rare cancer that has increased in incidence with the
HIV pandemic in Africa. The underlying cause of this cancer in HIV-infected patients from Botswana is not well
defined.
Results: Tissues were obtained from 28 OSSN and 8 pterygia patients. The tissues analyzed from OSSN patients
were 83% positive for EBV, 75% were HPV positive, 70% were KSHV positive, 75% were HSV-1/2 positive, and 61%
were CMV positive by PCR. Tissues from pterygium patients were 88% positive for EBV, 75% were HPV positive,
50% were KSHV positive, and 60% were CMV positive. None of the patients were JC or BK positive. In situ
hybridization and immunohistochemistry analyses further identified HPV, EBV, and KSHV in a subset of the tissue
samples.
Conclusion: We identified the known oncogenic viruses HPV, KSHV, and EBV in OSSN and pterygia tissues. The
presence of these tumor viruses in OSSN suggests that they may contribute to the development of this
malignancy in the HIV population. Further studies are necessary to characterize the molecular mechanisms
associated with viral antigens and their potential role in the development of OSSN.
Background
Ocular surface squamous neoplasia (OSSN) is a con-
junctival or corneal neoplastic growth that encompasses
the conditions of simple dysplasia to conjunctival intrae-
pithelial neoplasia (CIN) to invasive squamous cell carci-
noma [1]. Similar to cancer of the cervix, it has a
relatively high rate of recurrence after treatment and
may metastasize [2]. OSSN has gained interest in the
past few years in its association with the HIV pandemic
and its increase in incidence is collinear with the
increase in HIV [3]. Prior to the HIV pandemic, OSSN
was noted to occur predominantly in the elderly for
whom it is the third most common oculoorbital tumor
after melanoma and lymphoma [4,5]. In addition to
advanced age and male sex, other risk factors linked to
its pathogenesis have included ultraviolet light B rays
and mutation of the p53 tumor suppressor gene [6],
immunosuppression in organ transplant recipients [7],
cigarette smoking, and in some settings, HPV infection
[3,8]. In Africa, OSSN is becoming more common, more
aggressive, and more likely to affect young people, espe-
cially females [6].
In parallel with the dramatic increase of HIV in
Africa, several countries have noted a sharp rise in the
incidence of OSSN in HIV infected individuals such that
OSSN is currently the most common ocular tumor
among adults in Africa [6,9]. Africa has the highest rate
of HPV infection in the world, with an age-adjusted pre-
valence of 25.6% in women aged 15-74 years, followed
by South America (14.3%), Asia (8.7%), and Europe
(5.2%) [10]. In 2006, Waddell et al. investigated the role
of HIV infection in the etiology of corneo-conjunctival
intraepithelial neoplasia (CIN) and carcinoma [11]. The
prevalence of HIV infection in these cases was 64%
compared to 31% in controls [11]. These findings
demonstrated a strong association between increased
incidence of OSSN and HIV-1 infection as applied to all
tumor stages in Uganda. HIV-positive participants were
markedly immunosuppressed at the time of diagnosis
and their early mortality was high [11]. The majority of
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junctiva, which supports the concept of UV radiation as
a co-factor in the etiology of OSSN [11].
Pterygium is a raised benign growth on the eye that is
most often directly related to over-exposure to the sun
and dry, dusty conditions may also be a factor [12].
Pterygium in the conjunctiva is characterized by elasto-
tic degeneration of collagen and fibrovascular prolifera-
tion, and in some cases by “wing-like” conjunctival
overgrowth of the cornea [13]. Some studies have inves-
tigated human papillomavirus (HPV) as a risk factor for
the development of pterygia [14,15]. Interestingly, recent
studies have shown that pterygia can develop into
OSSN, and thus may be considered a pre-malignant
form of OSSN [16].
The aim of this study was to identify the viral etiologic
agent(s) associated with OSSN in the HIV-infected
population in Botswana. There are numerous examples
of associated malignancies in the HIV population, which
include CNS lymphomas with greater than 95% Epstein
Barr Virus (EBV) positivity [17], pleural effusion lym-
phomas which are usually co-infected with both tumor
gammaherpesviruses EBV and Kaposi’s sarcoma asso-
ciated herpes virus (KSHV) [18,19], AIDS associated B
and T cell lymphomas [20], Kaposi’s sarcoma (KS)[21],
Burkitt’s lymphoma (BL) [22], anogenital carcinomas
and papillomas [23], oral cancers [23,24] osteosarcomas
[25] mesotheliomas [25] and brain cancers
[2,18,21,23,26-28]. Also, the oncogenic papova virus
Human papillomavirus (HPV) infects keratinocytes caus-
ing benign and malignant tumors [1]. HPV proteins E6
and E7 are oncogenic and have been associated with cell
immortalization and antiapoptotic effects. The HPV
types 6, 11, 16, 18 and 33 have been identified in benign
and malignant conjunctival lesions [3].
The role of chronic latent viruses and their intermole-
cular interactions in combination with other environ-
mental factors in the context of HIV infection is likely
to be important for initiating and maintaining HIV-asso-
ciated malignancies. However, a causal role for these
viruses is difficult to ascertain at this time. Nevertheless,
infection with a range of viruses from the herspesviridae
family including HSV, HCMV, EBV, and KSHV may
contribute to the oncogenic process in OSSN, as has
been observed with other human cancers [29].
Methods
Patients
HIV-1 infected patients with conjunctival lesions seen at
Princess Marina Hospital, Gaborone, Botswana from
April 11 2007 to April 14 2008 were enrolled in this
study (IRB #805049 and Ministry of Health, Botswana
REF NO: PPME 13/18/1 Vol III 141). Briefly, patients
were identified by an ophthalmologist in the tertiary
care ophthalmology clinic at Princess Marina Hospital
which serves as the referral center for southern Bots-
wana. All HIV-1 positive patients diagnosed using a
HIV-ELISA (Abbott Laboratories, Hoofddorp, the Neth-
erlands) with clinical features suggestive of OSSN or
pterygium were enrolled the day before surgery. Written
consent was obtained from each subject in either Sets-
wana or English (according to subject’s preference). Tis-
sue specimens obtained in the ophthalmology operating
room were divided into two pieces by the ophthalmol-
ogy surgeon - one piece was sent for histopathologic
analysis and the other was immediately placed in tissue
transport medium for shipment to the University of
Pennsylvania viral oncology laboratory. Histologic con-
firmation of each clinical diagnosis was obtained from
the Botswana National Health Laboratory’sh i s t o -
pathologist. 39 patients participated in the study, how-
ever tissue samples of varying sizes were obtained from
only 36 cases. Tissues from patients included in this
study were 28 whose clinical diagnosis was OSSN and 8
with pterygia (Table 1). Only patients who signed the
University of Pennsylvania and Botswana Ministry of
Health Institutional Review Board consent forms were
included in this study. In this study all patients were
enrolled from the Botswana HIV clinic. Therefore we
were not able to obtain conjunctiva controls from HIV-
1 negative patients or those diagnosed with OSSN and
pterygia identified as HIV negative.
DNA extraction, in situ hybridization and
immunohistochemistry of tissue samples
Total cellular DNA was extracted from fresh OSSN and
pterygia tissues by digestion with proteinase K and phe-
nol-chloroform extraction as previously described [30].
PCR analysis was performed as previously described
[31-35] with each virus specific primer (see Figure 1C).
To support our PCR findings for the presence of HPV,
EBV, and KSHV in tissues we performed in situ hybridiza-
tion and immunohistochemistry on 5 μm thick paraffin-
embedded sections to detect virus specific antigens. We
noted alignment with the probes for HPV-16-L1 at 481-
511 bp (accession DQ155283), EBV-EBER at 1-26 bp
(accession J02078) and for KSHV-ORF-72 at 201-220 bp
(accession 009333). In situ hybridization probes for HPV-
16 or 18 [36], EBV-EBER [30], and KSHV-ORF-72 [34]
were labeled with digoxigenin-ddUTP (Dig) using a com-
mercial kit (Roche Inc., Indianapolis, IN) and used as
described previously [37]. We used commercial antibodies
HPV 16-L1 and HPV 18-E6 (DAKO Inc., Carpentaria,
CA), and monoclonal antibody S12 for EBV-LMP1, and
monoclonal antibody derived from KSHV encoded LANA
for immunohistochemistry [38]. Results from the ISH and
IHC were analyzed by a licensed histopathologist at the
University of Pennsylvania, School of Medicine.
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Case # Diagnosis Sex Age CD4 count HIV Viral load Affected Eye ARV Status Histology Results
1 OSSN M 45 40 <400 Right + SCC
2 Pterygium M 49 373 <400 Left + Pterygium
3 OSSN M 39 64 <400 Right + Pterygium
4 OSSN M 32 521 ND Right SCC
5 OSSN F 47 44 ND Right + SCC
6 OSSN M 43 174 120,000 Right SCC
*7 Pterygium F 29 ND ND Right + Pterygium
8 OSSN F 42 134 120,000 Left + SCC
9 OSSN F 27 171 <400 Left + NA
*10 OSSN M 40 ND <400 Right Severe dysplasia
11 OSSN M 38 326 <400 Left + Severe dysplasia
12 OSSN F 22 457 ND - NA
13 OSSN F 44 ND <400 Left + SCC
14 OSSN F 39 200 <400 Left + Pterygium
15 Pterygium F 38 725 ND Left Pterygium
16 Pterygium F 40 600 ND Left Pterygium
17 Pterygium F 38 491 ND Left Pterygium
18 OSSN F 44 314 ND Left NA
19 OSSN F 37 56 <400 Right + Pterygium
*20 OSSN M 48 21 <400 Right + SSCC
21 OSSN F 49 ND ND Right NA
22 OSSN F 30 90 ND Right SSCC
23 OSSN F 36 220 <400 Right + Severe dysplasia
24 OSSN F 35 ND 644,000 Right + Mild dysplasia
25 Pterygium F 39 293 <400 Left + Pterygium
26 Pterygium M 47 546 <400 Right Pterygium
27 Pterygium F 31 113 ND Left + Pterygium
28 OSSN M 50 87 <400 Right + SCC
29 OSSN F 34 192 ND Left SCC
30 Pterygium F 29 70 <400 Right + Pterygium
31 OSSN M 45 62 17,000 Left + NA
32 OSSN F 28 107 <400 Left + Severe dysplasia
33 OSSN F 42 236 342 Left Pterygium
34 OSSN M 33 94 81,972 Left + SCC
35 OSSN M 40 64 685,000 Right + Cancer in situ
36 OSSN F 36 38 200,000 Right + NA
37 OSSN F 49 ND ND Right Severe dysplasia
38 OSSN F 24 31 ND Left + Moderate dysplasia
39 OSSN F 44 121 ND Right SCC
* Tissue not available, NA - Not available
The table shows patient diagnosis, sex, age on entering study, CD4 counts, viral load, the eye affected, the retroviral therapy status of each patient, and histology
results. Tissues were not obtained from 3 patients and indicated with an asterisk. Patients #s 3, 14, 19, and 33 were diagnosed as OSSN but histology results
indicated that they were pterygia.
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To determine the HPV types and variants, analysis of
the PCR products were directly sequenced on an
automated sequencer according to manufacturer’s
protocol (Applied Biosystems Inc., Foster City, CA).
Briefly, HPV PCR products with consensus primers
were prepared and the reaction was run under stan-
dard cycle conditions of 96°C for 10 seconds, 55°C
for 5 seconds, and 60°C for 4 minutes for a total of
25 cycles. The PCR amplicons were then ethanol pre-
cipitated, dried briefly in a speed-vacuum, resus-
pended in Hi Di formamide and loaded onto the 3730
DNA analyzer (Applied Biosytems Inc., Foster City,
CA) for capillary electrophoresis and analysis.
Sequence analysis was done using Applied Biosystems
Sequence Analysis Software v5.3.1. The sequences
Figure 1 PCR analysis of OSSN for detection of human viruses. A. Representative PCR analysis of tumor virus detection from OSSN tumor
samples. For EBV PCR, LCL-2 10
5 cells which contain 20-50 copies of EBV per genome were used as positive control and distilled water as
control for PCR mix. For HPV, Hela 10
5 cells which contain 10-20 copies of HPV-18 per genome were used as positive control and distilled water
as control for PCR mix. Similarly for KSHV we used BCBL1 cells which contain 30-50 copies of KSHV per genome as positive control and distilled
water as control for PCR mix. The PCR products are shown after electrophoresis on a 3% agarose gel containing 100 ng/ml ethidium bromide.
PCR product size for each virus type is shown on the right side. We show representative gels showing the PCR results of which EBV was
detected in 83% of the samples, HPV in 75% of the samples, KSHV in 70% of the samples and CMV in 61% of the samples. We did not detect JC
and BK virus in any sample. B. Representative point mutations in HPV-L1 nucleotide and amino acid sequence variation in OSSN biopsies. We
detected HPV-16, 18, 45, 39, and 68 isolates. As shown, the changes were mainly missense and nonsense mutations. C. Shows the primer
sequences used in the PCR analysis of the oncogenic viruses in OSSN and pterygia tissues and probes used for in situ hybridization.
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sequences in GenBank.
Results
Patients were HIV positive and predominantly female
Tissue samples, sera, and plasma were collected from
39 patients with a diagnosis of OSSN or pterygium
from Princess Marina Hospital in Botswana (Table 1).
All patients were HIV-1 positive and 24 were on anti-
retroviral therapy (ARV) at the time of the study. Of
the 39 cases, 13 were male and 26 were female, 30 had
OSSN, and 9 had pterygia. The patients were young
with 38 cases under the age of 50 years old. CD4
counts were available for 32 patients and 20 patients
had counts below 200 cells/ml when ARVs were
started. Only 36 tissue samples were received for pro-
cessing-28 OSSN and 8 pterygia. Histological analysis
was obtained on the samples except for six where no
histological information was provided, and indicated
that some of the tumors were squamous cell carci-
noma (SCC), surface squamous cell carcinoma (SSCC),
pterygia, severe dysplasia, moderate, and mild dysplasia
(Table 1). No tissues were obtained from cases # 7, 10,
and 20 and so no further analyses were done. The
patients on ARVs had viral loads that were generally
low. However, a few had high copies (> 100,000
copies/ml) and were patients started on ARVs therapy
relatively recently. Viral load analysis was not com-
pleted for fifteen patients. No cases were bilateral,
however there was a preponderance for the left eye for
the few pterygium cases. The photographs represent
example showing a patient with OSSN (2A), and a clo-
ser view (2B). H and E staining of OSSN tissues typi-
cally shows in situ carcinoma characterized by full
thickness changes in nuclear to cytoplasm ratio,
nuclear pleomorphism, dyskeratotic cells, and the pre-
sence of koilocytes from HPV infection that could be
seen in some lesions (Figure 2C).
PCR analysis detected DNA from oncogenic viruses in
OSSN tissues
We performed PCR analysis on all tissues obtained to
determine whether any tumor viruses are associated
with OSSN. As shown in table 2, 30 (83%) cases were
EBV positive, 27 (75%) cases were HPV positive, 25
(70%) cases were KSHV positive, 22 (61%) cases were
CMV positive, 25 (70%) were HSV 1/2 positive, and
none of the patients had BK or JC. Using specific pri-
mers for identification of specific HPV types, we
detected HPV- 6, 11, 16, 18, 31, and 33 (Table 3). The
table shows that in both OSSN and pterygia samples
HPV-11, 16, and 18 were the most common. HPV-6, 31,
and 33 were rare and not detected in pterygia samples.
Results from the PCR analyses are depicted by the
representative sample of cases tested for EBV, HPV and
KSHV (Figure 1A). It is to be noted that a majority of
the cases tested were positive for all three oncogenic
viruses, albeit with different levels of intensity based on
difference in viral loads, cancer stage, and tissue size
from which the DNA was extracted. Some of the tissues
were co-infected with HPV/EBV/KSHV in different
combinations as determined by PCR (Table 2, and Fig-
ure 1). Interestingly, the data showed that the majority
of the samples had signals for both HPV-16 and 18 with
only 21% of OSSN positive for HPV-6 and 46% with sig-
nals for HPV-11 (Table 3). Moreover, 25% of OSSN tis-
sues were positive for HPV-31 and 4% of OSSN tissues
were positive for HPV-33 (Table 3). Therefore, in the
OSSN tissues from immunocompromised patients there
was a high degree of co-infection with multiple onco-
genic viruses as indicated by PCR, IHC, and ISH (Table
4 ) .I m p o r t a n t l y ,i ts h o u l da l s ob en o t e dt h a ta l lP C R
analyses done on archival tissues were negative or
inconclusive and therefore were not included in this
study (data not shown). This was likely due to the
inadequate or compromised conditions of the stored
tissues.
Figure 2 A. Representative photograph showing OSSN (A) and a closer view (B), C. H&E staining showing features of in situ carcinoma
characterized by full thickness changes in nuclear: cytoplasm ratio, nuclear pleomorphism, dyskeratotic cells, and presence of koilocytes.
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multiple oncogenic viruses
In situ hybridization was performed on sections from
fresh paraffin-embedded tissue utilizing HPV-16 L1,
EBV EBER, and KSHV ORF-72 specific oligonucleotide
probes to corroborate the above results, the specific
probes were detected using digoxigenin dd UTP label.
However, we did not perform ISH for CMV, HSV 1/2,
and other types of HPV due to insufficient tissue sec-
tions. We observed punctate and diffuse nuclear signals
indicative of integrated and episomal viral DNA gen-
omes respectively, as seen in the representative Case
#31 photographs (Figure 3D-F and 3G-I). The punctate
and episomal viral nuclear signals were more obvious in
H P Vs a m p l e s .I m p o r t a n t l y ,n os i g n a l sw e r eo b s e r v e d
with non specific probes or sense probes used as con-
trols (Figure 3A-C). These probes for EBER-sense,
KSHV-sense and HPV non-specific were used to clearly
demonstrate that these signals obtained were due to the
specific signals from the viral encoded transcripts and
was unlikely to be due to non-specific interactions from
cellular transcripts or deposited label. It should be noted
that the intensity of the in situ hybridization staining
was somewhat variable with some of the positive cells
closer to the surface of the lesions with clear nuclear or
perinuclear staining within the epithelial but little or
no detectable signals in the subepithelial layers and
the remaining epithelial tissue. For additional tissues
diagnosed as OSSN, similar analyses were done and
showed specific signals for the HPV-L1, EBV-EBER, and
KSHV-ORF-72 for some of the cases. The results
suggest similar patterns of infection with these viruses
a n dc o r r e l a t e dn i c e l yw i t ht h eP C Rd a t af r o mt h e
samples obtained (Table 4).
Immunohistochemical Analysis showed positive signals
for viral antigens in OSSN tissues
Based on PCR and in situ hybridization results in which
we detected viral genes in the DNA extract and tissues
of OSSN, we performed immunohistochemistry using
specific antibodies to identify viral antigens known to be
expressed by these viral agents in tissues. We noted spe-
cific signals with the antibodies to HPV- E6, EBV-
LMP1, and KSHV-LANA (Figure 4, panels D-I) from
representative Case # 31 compared to the controls. The
cells showed strong dark staining of the nuclei suggest-
ing positive signals for the viral antigen E6, and staining
Table 2 Oncogenic viruses identified by PCR in patient
samples
Case # Diagnosis HPV EBV KSHV CMV BK JC HSV 1/2
1 OSSN + + - - - - +
2 Pterygium + + + + - - +
3 OSSN + + + + - - +
4 OSSN + + + - - - +
5 OSSN + + - + - - +
6 OSSN + + + + - - +
8 OSSN + + + - - - +
9 OSSN + + - - - - +
11 OSSN + + + - - - -
12 OSSN + + + - - - -
13 OSSN -/+ + - + - - -
14 OSSN - - + + - - +
15 Pterygium - + + + - - +
16 Pterygium - + - + - - +
17 Pterygium - + + - - - +
18 OSSN - + + + - - +
19 OSSN - + + - - - -
21 OSSN - + + - - - -
22 OSSN - + - - - - -
23 OSSN - + + + - - +
24 OSSN - + + + - - -
25 Pterygium - + - + - - +
26 Pterygium + - + + - - -
27 Pterygium + + + - - - +
28 OSSN + + - - - - +
29 OSSN + - + + - - +
30 Pterygium + + - + - - -
31 OSSN + + + + - - +
32 OSSN - + - + - - +
33 OSSN + - + + - - +
34 OSSN + + + - - - -
35 OSSN + - + - - - -
36 OSSN + + - + - - +
37 OSSN + - + + - - +
38 OSSN + + + + - - +
39 OSSN + + + + - - +
Oncogenic viruses identified in each OSSN and pterygium patient as
determined by PCR analysis. Most cases tested positive for HPV, EBV, KSHV,
and HSV. HPV results for samples 14-24 were intriguing since most were
positive on IHC and ISH. None was positive for BK and JC.
Table 3 Proportion of HPV types identified by PCR in
OSSN and Pterygium tissues
Virus Type OSSN Pterygium
HPV-6 21% 0
HPV-11 46% 63%
HPV-16 61% 75%
HPV-18 54% 63%
HPV-31 25% 0
HPV-33 4% 0
Proportion of HPV types identified in patient samples by use of type specific
HPV primers, HPV types 6, 11, 16, 18, 31, and 33. It is noted that HPV-11, 16,
and 18 were common in both OSSN and pterygia cases, with HPV-6, 31, and
33 only detected in OSSN cases.
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intact showed dramatic signals suggesting the presence
of multiple viruses in this cancer. Positive immunostain-
ing was largely confined to the nuclei of the infected
superficial epithelial layers of the tissues for E6 and
L A N Ab u ta l s os h o w e ds i g n a ls throughout the cell
membrane or in focused regions of the membrane as
would be expected for LMP1. To determine the specifi-
city of the signals immunohistochemistry controls were
performed without primary antibody (Figure 4, Panels
A-C) and using tissue sections demonstrated to be nega-
tive for EBV, KSHV, and HPV by PCR (Figure 4, Panels
J-L). The results showed no detectable signals for any of
the sections developed (Figu r e4 ,p a n e l sA - C ,a n dJ - L
respectively) and supports the presence of these 3 onco-
genic viruses in the tissues tested that were diagnosed as
OSSN in HIV patients.
Multiple types of HPV were identified in individual
patients
Amplicons from PCR products were further purified and
sequenced using the consensus primers GP5+/GP6+.
We analyzed a 150-bp fragment of the L1 region of 36
cases for specific HPV types and variations. Using a 40
base sequence including the GP5+ priming site selected
as the signature for each HPV type online BLAST
sequence alignment algorithms of the L1 3’ end. The
results suggest that based on these analyses twenty six
HPV types were identified, with HPV- 7, 13, 16, 18, 39,
43, and 45 being the most common (Table 5). Impor-
tantly, all the tissues were positive for multiple HPV
types based on the analyses. We identified nucleotide
variations in the majority of samples. The variations
were mainly missense and silent mutations whose signif-
icance in maintenance of the virus is yet to be deter-
mined (Figure 1B). However, we observed that for HPV
39, the L1 C6741T variation was similar to C6733T and
C6903T [39] in cervical cancer in South American
population, and for HPV 18, the L1 G6731A variation
was similar in cervical cases in Africa at G6579A,
G6749A, and G6917A, while for HPV16, the L1 T6650G
and A6651C similarity was noted in cervical cancer
cases from India at T6889G and A6667C [40], (Figure
5).
Discussion
A dramatic increase in OSSN has been noted in sub-
Saharan Africa over the last 10 years in HIV population
[1]. In Uganda there has been an increase in incidence
especially among young people linked to HIV infection
Table 4 Oncogenic viruses identified in each patient by
IHC and ISH
Case # Diagnosis HPV EBV KSHV
IHC ISH PCR IHC ISH PCR IHC ISH PCR
1 OSSN - - + + + + + + -
2 Pterygium + + + + + + + + +
3 OSSN + + + + - + + - +
4 OSSN + - + + + + + + +
5 OSSN + + + - + + + + -
6 OSSN + + + + + + + + +
8 OSSN + + + +/- +/- + --+
9 OSSN + + + + + + + + -
11 OSSN + + + + + + + + +
12 OSSN + + + + + + + + +
13 OSSN -/+ -/+ -/+ + - + + + -
14 OSSN + + - + + - + - +
15 Pterygium + + - + + + + + +
16 Pterygium + + - + - + + + -
17 Pterygium + - - + + + + +/- +
18 OSSN + + - + + + + + +
19 OSSN + + - + + + + + +
21 OSSN + + - + + + + + +
22 OSSN + + - + + + + + -
23 OSSN + - - + + + + +/- +
24 OSSN + + - + + + + + +
25 Pterygium + +/- - + + + + + -
26 Pterygium + + + + + - + - +
27 Pterygium + + + + + + + + +
28 OSSN + +/- + + + + + + -
29 OSSN + + + + + - + + +
30 Pterygium + + + + + + + + -
31 OSSN + + + - - + +/- +/- +
32 OSSN - - - + + + + + -
33 OSSN + - + + + - + - +
34 OSSN - + + + + + + + +
35 OSSN + + + + + - + + +
36 OSSN + + + + - + + + -
37 OSSN - - + + + - + + +
38 OSSN + + + + + + + + +
39 OSSN + + + - - + + + +
+/- Indeterminate
Oncogenic viruses identified in each patient by Immunohistochemistry and In
situ hybridization. It is noted that for each of the samples analyzed for the
specific viruses-HPV-16/18, EBV, and KSHV, there was high concordance in IHC
and ISH. For each virus a column for PCR results has been added for
comparison. Due to lack of specimen we were unable to test for the other
viruses. No tissue samples were available for patients 7, 10, and 20.
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Gaborone currently indicates a pronounced increase in
incidence of OSSN in young HIV-1 infected individuals.
This initial study concurrently detected the presence of
multiple tumor viruses in OSSN tissues. For the first
time we showed the presence of HPV, EBV, KSHV, and
CMV in ocular tissues in HIV/AIDS patients. Associa-
tion of viruses with human cancers have already been
reported, such as KSHV with KS and PEL [41], EBV
with primary CNS lymphoma [17], nasopharyngeal car-
cinoma [26], and Burkitt’s lymphoma [22], HPV with
cervical cancer [2], anal cancer [42], and testicular can-
cer [43], However, the level of contribution by HIV to
the development of human malignancies remains
unclear and is likely to be through several mechanisms.
Infection and establishment of latency are mediated by
viral proteins expressed in infected cells. Importantly,
the immunomodulatory mechanisms used by one virus
may actually enhance or benefit the activity or replica-
tion of other viruses. Many of these viruses (for exam-
ple, HPV, CMV, and EBV) are quite common in the
human population [44], but do not always lead to devel-
opment of malignancies in healthy individuals with a
competent immune system. However, infection with
HIV resulting in immunosuppression may eventually tip
the balance in favor of the tumor viruses, leading to an
increased risk of cancer in the immune compromised
individuals. The localization of these oncogenic proteins
in the OSSN tissues show association, however estab-
lishment of a causal effect by any of the viruses, or a
multiple of the viruses in an HIV atmosphere has yet to
be fully confirmed. Determining the pathways involved
in the initiation and establishment of the cancers in
HIV patients compared to non-HIV patients will give us
a better understanding of the interplay of the different
oncogenic viral proteins within the normal immune
Figure 3 In situ hybridization.P a n e l sA-C shows results from Sense probe negative controls with no detectable nuclear staining. Panels D-F
the positive cells of tissue sections probed with HPV-L1, EBV-EBER, and KSHV-ORF72 showed dark brown staining of the nucleus. The probes did
not detect all viruses in all tumor cells, however, HPV, EBV, and KSHV were detected in some regions. Panels G-I shows a higher magnification of
60× compared to panels D-F which showed magnification of 40×.
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Page 8 of 13system and immunosuppressed system. Though we have
shown the presence of these viral proteins in the OSSN
tissue, some investigators have not identified viral
sequences in squamous cell conjunctival carcinoma
(SCCC) which has also increased in the HIV infected
population and has been suspected of having viral etiol-
o g y[ 4 5 , 4 6 ] .T h e r e f o r e ,m o r es t u d i e sa r ec l e a r l yn e e d e d
to fully establish a role for these viruses in OSSN.
The localization of different tumor viruses in similar
tissue sections suggest that these viruses may functionally
interact to contribute to the OSSN phenotype. Similar to
our findings of HPV and EBV in ocular tissues, Prayitno
reported that in 19 cervical carcinoma samples 89% were
positive for HPV and 68% were positive for EBV [47].
Nakamura et al suggested that HPV probably does not
act alone in initiating ocular neoplasia, but that other
factors including the ultraviolet light were involved [37].
Whereas studies involving HPV and cervical cancer have
been associated with oncogenic HPV-16 and 18, our
study identified HPV-6, 7,16, 18, 31, 45, and 97 in DNA
from the OSSN and pterygia tissues as determined by
PCR. Interestingly, we detected nucleotide sequences
from HPV-1, 3, 7, 13, 16, 18, 29, 31, 33, 39, 40, 43, 44, 45,
55, 59, 61, 68, 70, 74, 77, 85, 89 91, and 97 by sequencing
PCR amplicons from the different tissues. Some of the
sequence alignments had scores greater than 80% with
specific HPV types indicating presence of these HPV
types or their variants in some of the samples. This sug-
gests exposure to many types of HPV in this population,
some of which are oncogenic, which with other factors
may trigger cell proliferation leading to OSSN and other
cancers in the immunocompromised patients. The
Figure 4 Representative Immunohistochemistry results of selected OSSN tissues.P a n e l sA-C shows no nuclear staining in the negative
controls, Panels D-F show positive cells as dark brown staining of the nucleus with HPV-E6 antibody, as well as positive staining for LMP1 and
LANA using EBV-LMP1 hybridoma supernatant and KSHV-LANA specific antibody. Panels G-I shows a higher magnification of 60× compared to
panels D-F taken at 40×. Panels J-L are immunohistochemistry results for negative samples showing no detectable staining which would
represent positive signals.
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Page 9 of 13selection pressure that may exist as a consequence of
competition between opportunistic infections may
further lead to mutations occurring in the HPV types as
well as the other infectious agents. Interestingly, there
was a significant amount of amino acid variation within
the cases to suggest different HPV types when each
sequence was aligned with the specific HPV prototype.
To corroborate the PCR results we performed in situ
hybridization and immunohistochemistry studies. These
results showed that in the invasive OSSN tissues the
viruses were localized in similar tissue sections. Some of
the viral genomes are likely to be integrated by their
punctate signals and episomal viral DNA by their diffuse
signal throughout the nucleus [24]. The number of cells
positive for viral signals were modest, possibly a factor
of the limited size of tissues tested, relatively small size
of the tissue obtained for analysis, and lower sensitivity
compared to PCR. Previous reports have suggested that
infection with more than one HPV type enhances cervi-
cal cancer and oral squamous carcinoma [23]. Also,
Mirzamani et al reported co-infections with EBV and
HPV-16/18 in nasopharyngeal carcinoma (NPC) patients
and concluded that both viruses were important in con-
tributing to the pathogenesis of NPC [26]. It is not
known if cases with OSSN without HIV infection had
similar outcome with HPV and other viruses as we were
unable to obtain these tissue samples. Moubayed et al
reported HPV-6/11, HPV-16, and HPV-18 in a Tanza-
nian study, with the conclusion that it was HPV-16 and
HPV-18 that was associated with OSSN [48]. They
noted that the intensity of in situ hybridization was
highly variable ranging from barely detectable to a few
grains over some cells located near the surface of the
lesions [48]. As in some of our hybridization results
they noted nuclear or perinuclear staining within the
epithelial lesions and a complete absence of hybridiza-
tion signals in the subepithelial layers and the surround-
ing unaffected epithelium.
The significance of all the HPV types identified with
respect to OSSN oncogenesis in individual patients, and
specifically the infection with multiple oncogenic HPV
types-both high risk and low risk, EBV, and KSHV
viruses requires careful examination. Some studies have
indicated that the oncogenic capacity of HPV variants
may also differ between geographic regions based on
HLA allele distribution in these populations [40]. The
unknown impact of HLA allele differences, HPV var-
iants, and other oncogenic viruses in this HIV-1 infected
population is of significance and warrants further
investigation.
In tropical countries secondary immunodeficiency
attributable to chronic inflammation caused by parasitic
or viral infections might contribute to tumorigenesis.
The high frequency of coinfection of HPV, EBV, KSHV,
CMV, and HIV in the OSSN patients may be a result of
cooperative and complementary interactions of the
viruses. In addition, we suggest that the disease might
be more aggressive in HIV patients due to their immune
dysfunction, abnormal cytokine and chemokine expres-
sion, growth factor production and exposure to ultravio-
let rays. In this sample we cannot determine if the
Table 5 HPV Types detected in patient samples by
sequencing using consensus primers GP5+/GP6+
Case # HPV type
1 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
2 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
3 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
4 7,13,16,18,39,40,43,59,61,68,70,77,91,97
5 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
6 7,13,16,18,39,40,43,59,68,70,77,91,97
8 7,13,16,18,29,39,40,43,45,59,61,68,70,77,85,91,97
9 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
11 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
12 16,18,39,40,43,45,59,61,68,70,77,85,91,97
13 7,13,16,18,39,40,43,45,59,61,68,70,74,85,91,97
14 16,18,29,39,40,43,45,59,68,70,85,91,97
15 7,13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
16 7,13,16,18,39,40,43,45,59,61,68,70,74,77,85,91,97
17 7,13,16,18,29,39,40,43,45,59,61,68,70,77,85,91,97
18 7,16,18,39,40,61,70,77,85,91,97
19 16,18,39,40,43,45,61,70,77,85,91,97
21 7,13,16,40,45,70,77,85
22 7,13,16,39,43,45,70,85
23 7,13,43,45,70,77,85
24 7,43,45,85
25 13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
26 13,16,18,39,40,43,45,59,61,68,70,77,85,91,97
27 1,3,7,11,13,16,18,39,40,43,45,59,61,68,70,77,85,89,91,97
28 29,43,45,59,85
29 45,59,68,70,85
30 1,3,7,11,13,16,18,39,40,43,45,59,61,68,70,77,85,89,91,97
31 16,18,43,45,59,68,70
32 16,18,43,45,59,61,68,70
33 1,13,16,18,39,40,43,44,45,55,59,61,68
34 7,13,16,18,39,43,45,59,61,68,97
35 7,16,18,39,40,43,45,59,61,68,74
36 16,18,39,45,59,61,68,77,97
37 7,13,16,18,39,43,45,59,61,68,77,97
38 7,13,16,18,39,40,43,44,45,55,59,68,74,77,97
39 7,18,39,40,43,59,61,68,74,77,91,97
HPV types identified in patient samples by sequencing with the consensus
primer GP5+/GP6+. The most commonly identified HPV type in both OSSN
and pterygium tissues included the high risk HPV-18, 16, 45, 39, 59, and 68.
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Page 10 of 13Figure 5 Nucleotide and amino acid sequence variation in OSSN and pterygia patients. Shown are representative samples of the most
common HPV types detected by sequencing using GP5+/GP6+ primers of the L1 region. The table shows nucleotide variation and amino acid
changes. The top 4 rows show the nucleotide position, the 5
th row shows the HPV reference nucleotide sequence, the 6
th row shows the
variation in patient nucleotide sequence, and the 7
th row is the resulting variant amino acid sequence. In each HPV type, the variations were the
same for each study case in the selected nucleotide sequence with some differences upstream and downstream in the different subjects, except
case #15 which varied in a specific nucleotide in all HPV types, besides HPV-1.
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Page 11 of 13patients were initially infected with HPV, or HIV and
other oncogenic viruses before occurrence of OSSN, or
if some of the viruses were opportunistic infections as a
result of OSSN disease or HIV infection. The effect of
latency in ubiquitous viruses like EBV, HPV and high
prevalence of sexually transmitted HSV and KSHV is
not clear in this OSSN population. It has been reported,
and we also note that the course of OSSN is more rapid
in HIV infected patients and the occurrence is increas-
ing in younger patients with HIV at a higher rate [3,6].
In HIV infected patients, it is not known at what stage
OSSN occurs. Spitzer et al in a Malawi study reported
that OSSN was the first detectable sign of HIV infection
in the majority of cases [7].
Conclusion
This study investigating the link between oncogenic
viruses in OSSN in the HIV population suggests that
multiple viral agents may have a role in development of
this disease. The interaction between different viral anti-
gens and their regulatory activities in immunocompro-
mised individuals will contribute to cell survival and
proliferation in the infected cells. Clearly, further study
is warranted to understand the molecular processes
involved in the increased incidence of OSSN in the HIV
population.
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